MENU
+Compare
NTLA
Stock ticker: NASDAQ
AS OF
Aug 22 closing price
Price
$10.52
Change
+$0.40 (+3.95%)
Capitalization
1.13B

NTLA Intellia Therapeutics Forecast, Technical & Fundamental Analysis

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics... Show more

Industry: #Biotechnology
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NTLA with price predictions
Aug 22, 2025

NTLA sees MACD Histogram just turned negative

NTLA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 29, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NTLA moved out of overbought territory on July 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NTLA as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

NTLA moved below its 50-day moving average on August 18, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on August 20, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NTLA broke above its upper Bollinger Band on July 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NTLA entered a downward trend on August 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.579) is normal, around the industry mean (19.350). P/E Ratio (0.000) is within average values for comparable stocks, (54.748). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.643). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (20.408) is also within normal values, averaging (304.421).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NTLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NTLA is expected to report earnings to rise 1.85% to -99 cents per share on November 06

Intellia Therapeutics NTLA Stock Earnings Reports
Q3'25
Est.
$-1.00
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.17
Q4'24
Beat
by $0.07
Q3'24
Beat
by $0.05
The last earnings report on August 07 showed earnings per share of -98 cents, beating the estimate of -102 cents. With 3.22M shares outstanding, the current market capitalization sits at 1.13B.
A.I. Advisor
published General Information

General Information

a developer of proprietary, potentially curative therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Erie Street
Phone
+1 857 285-6200
Employees
526
Web
https://www.intelliatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMPAX26.010.69
+2.73%
Calvert Small/Mid-Cap A
FADTX134.062.39
+1.82%
Fidelity Advisor Technology A
MENIX9.650.12
+1.26%
Madison Covered Call & Equity Income I
AWIIX16.340.15
+0.93%
CIBC Atlas Income Opportunities Instl
DIFFX12.480.09
+0.73%
MFS Diversified Income R3

NTLA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+3.90%
VCYT - NTLA
69%
Closely correlated
+5.33%
CRSP - NTLA
67%
Closely correlated
+2.84%
BEAM - NTLA
64%
Loosely correlated
+3.94%
RXRX - NTLA
56%
Loosely correlated
+3.35%
AXON - NTLA
55%
Loosely correlated
+0.36%
More

Groups containing NTLA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+3.90%
NTLA
(2 stocks)
79%
Closely correlated
+3.37%